Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation collaboration and integrity. Rezolute’s lead investigational therapy RZ358 (ersodetug) is a fully human monoclonal antibody in late-stage development for hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI) including congenital hyperinsulinism (cHI) the most common cause of persistent hypoglycemia in infants and children. The Senior Manager Scientific Communications & Medical Education will develop and manage Rezolute’s core scientific content and medical review activities for RZ358 across congenital and tumor HI. Key responsibilities include standard response … Sign In to View